Clinical Impact of Bortezomib in Frontline Regimens for Patients with Multiple Myeloma

Clinical Impact of Bortezomib in Frontline Regimens for Patients with Multiple Myeloma Rami Manochakian, Kena C. Miller, Asher A. Chanan-Khan Oncologist 2007; 12: 978-990 Author Information and Disclosures Target Audience: Method of Physician Participation: Read course materials, complete course quiz and evaluation form (required). Learning Objectives After completing this course, the reader should be able to: Discuss the efficacy of bortezomib as part of primary therapy for patients with multiple myeloma. Describe the safety of bortezomib and bortezomib-based regimens in patients with previously untreated multiple myeloma. Identify new management options for patients with treatment-naïve multiple myeloma. The NIH/FAES designates this educational activity for a maximum of 1.00 AMA PRA Category 1 Credit™. Physicians should only claim credit commensurate with the extent of their participation in the activity.

CME Activity Information Accreditation CME Instructions For Credit Privacy Statement Hardware/Software Requirements Release Date: August 31, 2007 Most Recent Review: August 31, 2007* Most Recent Update: August 31, 2007 Date Credit Expires: August 31, 2009 Time to Complete: 1 hour Medium: Internet Online *Click here to learn more about our review process.

• Take this course